RENAL PATIENTS
Adult FERINJECT prescription and consent form
(ferric carboxymaltose 1000mg of iron in 20mL)

THIS FORM IS NOT TO BE USED FOR HAEMODIALYSIS PATIENTS; THOSE PATIENTS RECEIVE VENOFER

Name:

Date of Birth: DD / MM / YYYY

Hospital Number: Affix Patient's Label Here

Ward: Consultant:

LOCATION OF INFUSION

❑DATU ❑AEC ❑Renal Unit OTHER:

Weight : **kg** **Allergies:**

BLOOD RESULTS:

Saturation %	Ferritin ng/mL	Haemoglobin g/L	Iron micromol/L

❑ Tick here if the patient receives erythropoietin.

Interpretation of blood results:

Saturation >30%

Ferinject should NOT be used.

Saturation 20-30% and Haemoglobin > 100 g/L

Ferinject is NOT required.

Saturation 20-30%, Haemoglobin < 100 g/L and ferritin <500 ng/mL

Ferinject is required.

Saturation <20% and ferritin <100 ng/mL

If the patient doesn't receive erythropoietin, Ferinject is required if Haemoglobin <100 g/L.

If the patient receives erythropoietin, Ferinject is required if Haemoglobin <120 g/L.

PRESCRIPTION Administration date _ _ /_ _ / _ _	
DOSE	……mg (Max 1000mg)
PRESCRIBER	**Sig.**_____**Date:** __ / __ / __ **PRINT NAME:** _____**Bleep:** _____
PHARMACY	**Clinical** **Disp** **Accuracy**

ADMINISTRATION RECORD Date _ _ /_ _ / _ _

SCHEDULE	TIME	PULSE	BP (mmHg)	INFUSION SITE	GIVEN BY (Sig.)	CHECKED BY (Sig.)
0 MINS						
+5 MINS				BN: ……		
+ 30 MINS				EXP: ……		

Give in at least 100mL sodium chloride 0.9% over at least 15 minutes (max. volume 250mL)

After 6 weeks, recheck haemoglobin and iron studies and consider a further 500mg dose if necessary.

Only administer by staff trained to evaluate/manage anaphylactic reactions in areas with full resuscitation facilities available

CONTRAINDICATIONS:
- **Hypersensitivity to Ferinject, its excipients or other parenteral iron products**
- **Evidence of iron overload/disturbance of iron utilisation**
- **First trimester of pregnancy**
- **Anaemia not attributed to iron deficiency anaemia**

CAUTIONS:
- **Asthma, eczema, atopic allergies, hepatic impairment**
- **May exacerbate infections**
- **Risk of permanent skin staining-STOP infusion submit yellow card**
- **Acute renal failure - see guidelines for anaemia in patients with CKD (2022)**
- **Hypophosphataemia - osteomalacia and fractures risk with repeated multiple/high doses. Monitor levels in at risk patients**

References:
1. Injectable Medicines Guide - Medusa (2022*). Ferinject IV Monograph version 6* [online] Available at: https://injmed.wales.nhs.uk/IVGuideDisplay.asp[Accessed 29/06/2022].
2. Summary of Product Characteristics (2022).*Ferinject (Ferric Carboxymaltose) (Emc)*. [online] Available at:https://www.medicines.org.uk/emc/product/5910/smpc[Accessed 29/06/2022]

Created by: Pharmacy Dept. Noble's Hospital Issue date: September 2023 Review date: September 2025

INFORMED CONSENT

When you must not be given Ferinject

If you are hypersensitive (allergic) to ferric carboxymaltose or any of the other ingredients of Ferinject
If you are allergic to other parenteral (IV) iron products
If you have anaemia **not** caused by iron deficiency
If you have iron overload (too much iron in your body) or disturbances in utilisation of iron.
If you are under the age of 18 years.
If you are in the first 3 months of pregnancy
If your iron deficiency can be treated with oral iron tablets or liquids instead of into the vein.

How Ferinject is given

By infusion, you may receive up to 20 mL of Ferinject, corresponding to 1000mg of iron, up to once a week directly into the vein. Because Ferinject is diluted with sodium chloride solution for the infusion, it may have a volume of up to 100-250 mL and it will appear as a brown solution.

You will be observed for about 30 minutes by your doctor or nurse after each administration, with your blood pressure and pulse measured during this time.

I understand the benefits and risks of Ferinject iron infusion administration which may include but is not limited to:

- Severe allergy – which in rare cases may be fatal
- Paravenous leakage – leakage of medication at the injection site potentially leading to permanent brown discolouration and irritation to the skin
- Skin irritation
- Headache, dizziness, tachycardia, increased heart rate or blood pressure changes
- Nausea, abdominal pain, constipation, diarrhoea, vomiting
- Minor reactions can occur up to 48 hours after the infusion
- Low phosphate level

Please discuss any questions you may have with a health care professional.

I _____(PRINT NAME) have read and understand the above information provided to me, including the risks of this medication and I consent to Ferinject infusion being administered. I have had an opportunity to discuss this with a health care professional.

SIGNATURE:_____ Date: _____

Health care professional:

PRINT NAME: _____ POSITION: _____

SIGNATURE:_____ Date: _____